The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Open accessAbstract
BACKGROUND: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population. METHODS: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol. RESULTS: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003). CONCLUSIONS: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation. 6”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2005, a causative association was established between the presence of loss-of-function mutations in PCSK9 and lifelong reductions in LDL-C associated with lower CHD risk (3).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic studies have shown that carriage of PCSK9 loss-of-function alleles is associated with lower LDL cholesterol levels and a reduced risk of myocardial infarction.7,8”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that drugs that ultimately reduce LDL-C level predominantly through upregulation of LDL receptor expression should, barring any off-target adverse effects, lead to clinical benefit in proportion to the degree of LDL-C reduction.64”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike gain-of-function PCSK9 variants (7), loss-of-function (LOF) variants enhance LDLR levels and promote LDLc clearance (4, 8).”
From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Whereas PCSK9 loss-of-function mutations carriers with lifelong reductions in LDL-C and coronary heart disease incidence, were not initially found at significantly reduced risk of stroke (3, 72), a much larger study of the UK Biobank database described the first genetic evidence of a protective effect of the R46L loss-of-function mutation on PCSK9 on ischemic stroke (73).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
In the citing paper
“and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C [2,51].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“The remarkable consistency among these studies, in addition to biological and experimental evidence, provides compelling evidence that LDL-C is causally associated with the risk of ASCVD”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“Both studies had relatively short follow-up periods and the evidence from statin trials indicates that the clinical benefits of LDL-lowering may only emerge after about 1 year [51], so these trials may have underestimated the potential impact of longer-term treatment [120,290].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“These developments have enabled researchers to bridge the gap between the monogenic and polygenic realms, identifying common variant modifiers of monogenic phenotypes contributing to the variable expression of rare, large-effect alleles26,93, and low-frequency and rare variants that influence common multifactorial traits94,95.”
From A brief history of human disease genetics (2020) · cites this paper as [95]
In the citing paper
“At the same time, it has become increasingly evident now that not only the magnitude of LDL-C lowering is important but that the duration of exposure to elevated LDL-C levels is equally important [11,16,38].”
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“The exceptionally low rates of CV events observed in patients carrying mutations in PCSK9 or other similar genes despite only modestly low LDL-C levels strongly support this notion [11].”
In the citing paper
“Hobbs and Cohen sequenced the gene (126, 127) and identified low-frequency common variants (0.5 to 1%), which allowed epidemiological research documenting a protective effect on myocardial infarction (128).”
From Genetic Mapping in Human Disease (2008) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
(1989) · PubMed · Cited by 3,139
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
CORONARY DISEASE AMONG UNITED STATES SOLDIERS KILLED IN ACTION IN KOREA
Enos, W. F. (1953) · JAMA · doi:10.1001/jama.1953.03690120006002 · Cited by 891
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,025
Persson, L., Cao, G., Ståhle, L., Sjöberg, B. G., Troutt, J. S., Konrad, R. J., Gälman, C., Wallén, H., Eriksson, M., Hafström, I., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.214130 · Cited by 165
Bachmann, J. M., Willis, B. L., Ayers, C. R., Khera, A., & Berry, J. D. (2012) · Circulation · doi:10.1161/circulationaha.111.065490 · Cited by 164
Landmesser, U., Chapman, M. J., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L. S., Wiklund, O., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw480 · Cited by 164
Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 163
Jurgens, S. J., Choi, S. H., Morrill, V. N., Chaffin, M. D., Pirruccello, J. P., Halford, J. L., Weng, L.-C. C., Nauffal, V., Roselli, C., Hall, A. W., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-01011-w · Cited by 166
Brunner, E. J., Mika Kivimaki, B., Witte, D. R., Lawlor, D. A., Smith, G. D., Cooper, J. A., Miller, M. A., Lowe, G. D. O., Rumley, A., Casas, J. P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050155 · Cited by 162
Unique roles of rare variants in the genetics of complex diseases in humans
Momozawa, Y., & Mizukami, K. (2021) · Journal of Human Genetics · doi:10.1038/s10038-020-00845-2 · Cited by 161
Zhang, Y., Eigenbrot, C. W., Zhou, L., Shia, S., Li, W., Quan, C. L., Tom, J., Moran, P., Lello, P. D., Skelton, N. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514067 · Cited by 161
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Gencer, B., Montecucco, F., Nanchen, D., Carbone, F., Klingenberg, R., Vuilleumier, N., Aghlmandi, S., Heg, D., Räber, L., Auer, R., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv637 · Cited by 161
Krauss, R. M., Mangravite, L. M., Smith, J. D., Medina, M. W., Wang, D., Guo, X., Rieder, M. J., Simon, J. A., Hulley, S. B., Waters, D. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.708388 · Cited by 160
Morita, S. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00716 · Cited by 161
Liver fat accumulation is associated with circulating PCSK9
Ruscica, M., Ferri, N., Macchi, C., Meroni, M., Lanti, C., Ricci, C., Maggioni, M., Fracanzani, A. L., Badiali, S., Fargion, S. R., et al. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1188328 · Cited by 160
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Cardiovascular risk and dyslipidemia among persons living with HIV: a review
Maggi, P., Biagio, A. D., Rusconi, S., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Martinelli, C. V., Nunnari, G., Sighinolfi, L., Spagnuolo, V., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2626-z · Cited by 159
Catapano, A. L., & Papadopoulos, N. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.044 · Cited by 158
Genetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 158
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
McNutt, M., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., & Lagace, T. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808802200 · Cited by 157
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Li, ., Tumanut, C., Gavigan, J.-A., Huang, W.-J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070664 · Cited by 157
Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup
Xu, H., Sheng, S., Luo, W., Xu, X.-F., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277161 · Cited by 157
Boyd, J. H., Fjell, C. D., Russell, J. A., Sirounis, D., Cirstea, M. S., & Walley, K. R. (2016) · Journal of Innate Immunity · doi:10.1159/000442976 · Cited by 156
Wang, K., Dickson, S. P., Stolle, C. A., Krantz, I. D., Goldstein, D. B., & Hakonarson, H. H. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.04.003 · Cited by 156
Cariou, B., May, C. L., & Costet, P. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.018 · Cited by 154
Diogo, D., Bastarache, L. A., Liao, K. P., Graham, R., Fulton, R. S., Greenberg, J. D., Eyre, S., Bowes, J., Cui, J., Lee, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122271 · Cited by 154
Burgess, S., Mason, A. M., Grant, A. J., Slob, E. A. W., Gkatzionis, A., Zuber, V., Patel, A. R., Tian, H., Liu, C., Haynes, W. G., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.017 · Cited by 157
Physiological and pathological implications of cholesterol
Cortés, V. (2014) · Frontiers in bioscience · doi:10.2741/4216 · Cited by 153
Aung, T., Ozaki, M., Lee, M., Schlötzer-Schrehardt, U. M., Þorleifsson, G., Mizoguchi, T., Igo, R. P., Haripriya, A., Williams, S. E. I., Astakhov, Y. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3875 · Cited by 153
Significant sparse polygenic risk scores across 813 traits in UK Biobank
Tanigawa, Y., Qian, J., Venkataraman, G. R., Justesen, J. M., Li, R., Tibshirani, R. J., Hastie, T. J., & Rivas, M. A. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010105 · Cited by 153
Biological and functional multimorbidity—from mechanisms to management
Langenberg, C., Hingorani, A. D., & Whitty, C. W. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02420-6 · Cited by 153
Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., & Spraggon, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703402104 · Cited by 153
Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms
Rusu, V., Hoch, E., Mercader, J. M., Tenen, D. E., Gymrek, M., Hartigan, C. R., DeRan, M., von Grotthuss, M., Fontanillas, P., Spooner, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.011 · Cited by 152
Self-citationYeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Explaining additional genetic variation in complex traits
Robinson, M. R., Wray, N. R., & Visscher, P. M. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.02.003 · Cited by 152
A cholesterol-lowering VLP vaccine that targets PCSK9
Crossey, E., Amar, M. J., Sampson, M. L., Peabody, J., Schiller, J. T., Chackerian, B., & Remaley, A. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.044 · Cited by 151
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes
Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.017 · Cited by 150
COPII — a flexible vesicle formation system
Miller, E. A., & Schekman, R. W. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.04.005 · Cited by 150
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 149
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
Benito‐Vicente, A., Uribe, K. B., Jebari‐Benslaiman, S., Galicia-García, U., Ostolaza, H., & Martín, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113426 · Cited by 151
The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk
Nayor, M. G., Brown, K., & Vasan, R. S. (2021) · Circulation Research · doi:10.1161/circresaha.120.315890 · Cited by 149
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 148
The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors
Neelakantan, N., Seah, J. Y. H., & van Dam, R. M. (2020) · Circulation · doi:10.1161/circulationaha.119.043052 · Cited by 148
Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk
Aragam, K. G., & Natarajan, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.315928 · Cited by 148
Rashid, S., Tavori, H., Brown, P. E., Linton, M. F., He, J., Giunzioni, I., & Fazio, S. (2014) · Circulation · doi:10.1161/circulationaha.113.006720 · Cited by 147
Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes
Flannick, J. A., Johansson, S., & Njølstad, P. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.50 · Cited by 148
Norata, G. D., Tavori, H., Pirillo, A., Fazio, S., & Catapano, A. L. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw194 · Cited by 147
Cariou, B., Ouguerram, K., Zaïr, Y., Guérois, R., Langhi, C., Kourimate, S., Benoit, I., May, C. L., Gayet, C., Belabbas, K., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.194191 · Cited by 146
Bouhairie, V. E., & Goldberg, A. C. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.001 · Cited by 146
Genetics of Coronary Artery Disease
Roberts, R. (2014) · Circulation Research · doi:10.1161/circresaha.114.302692 · Cited by 144
Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases
Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903618 · Cited by 144
The Illusion of Inclusion — The “All of Us” Research Program and Indigenous Peoples’ DNA
Fox, K. (2020) · New England Journal of Medicine · doi:10.1056/nejmp1915987 · Cited by 144
Bauer, D. E., & Orkin, S. H. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.08.001 · Cited by 143
Lalani, S. R., Liu, P., Rosenfeld, J. A., Watkin, L. B., Chiang, T., Leduc, M. S., Zhu, W., Ding, Y., Pan, S., Vetrini, F., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.12.008 · Cited by 143
Self-citationExome sequencing and complex disease: practical aspects of rare variant association studies
Do, R., Kathiresan, S., & Abecasis, G. R. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds387 · Cited by 143
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders
Fiorucci, S., Cipriani, S., Baldelli, F., & Mencarelli, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.11.001 · Cited by 142
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
Cui, Q., Ju, X., Yang, T., Zhang, M., Tang, W., Chen, Q., Hu, Y. S., Haas, J. V., Troutt, J. S., Pickard, R. T., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.027 · Cited by 141
Genetic Determinants of Lipids and Cardiovascular Disease Outcomes
Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason, A. M., Bell, S., Gill, D., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002711 · Cited by 141
Koromina, M., Pandi, M.-T., & Patrinos, G. P. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0151 · Cited by 140
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Sun, X., Essalmani, R., Day, R. W., Khatib, A., Seidah, N. G., & Prat, A. (2012) · Neoplasia · doi:10.1593/neo.121252 · Cited by 140
Mitchell, T. S., Chao, G., Sitkoff, D. F., Lo, F., Monshizadegan, H., Meyers, D. S., Low, S., Russo, K., DiBella, R. A., Denhez, F., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214221 · Cited by 140
Improved cytosine base editors generated from TadA variants
Lam, D. K., Feliciano, P. R., Arif, A., Bohnuud, T., Fernandez, T. P., Gehrke, J. M., Grayson, P., Lee, K. D., Ortega, M. A., Sawyer, C. B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01611-9 · Cited by 140
Mayer, G., Poirier, S., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805971200 · Cited by 139
Feedback Regulation of Cholesterol Uptake by the LXR–IDOL–LDLR Axis
Zhang, L., Reue, K., Fong, L. G., Young, S. G., & Tontonoz, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.250571 · Cited by 137
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation
Cao, Z., Conway, K. L., Heath, R. J. W., Rush, J. S., Leshchiner, E. S., Ramirez‐Ortiz, Z. G., Nedelsky, N. B., Huang, H., Ng, A., Gardet, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.005 · Cited by 137
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 137
Bottomley, M. J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Surdo, P. L., Calzetta, A., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808363200 · Cited by 137
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
Mika Kivimaki, B., Shipley, M. J., Ferrie, J. E., Singh‐Manoux, A., Batty, G. D., Chandola, T., Marmot, M. G., & Smith, G. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61688-8 · Cited by 136
González, L., & Trigatti, B. L. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.010 · Cited by 136
Li, Z., Zhang, B., Liu, Q., Tao, Z., Ding, L., Guo, B., Zhang, E., Zhang, H., Meng, Z., Guo, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104543 · Cited by 136
Detecting rare variants for complex traits using family and unrelated data
Zhu, X., Feng, T., Li, Y., Lu, Q. L., & Elston, R. C. (2009) · Genetic Epidemiology · doi:10.1002/gepi.20449 · Cited by 135
Moutsianas, L., Agarwala, V., Fuchsberger, C., Flannick, J. A., Rivas, M. A., Gaulton, K. J., Albers, P. K., McVean, G., Boehnke, M., Altshuler, D., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005165 · Cited by 135
Ni, Y. G., Marco, S. D., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011445 · Cited by 135
Raal, F. J., Panz, V. R., Immelman, A., & Pilcher, G. J. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000028 · Cited by 135
Melone, M., Wilsie, L. C., Palyha, O. C., Strack, A. M., & Rashid, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.064 · Cited by 134
Protective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 134
Rutten, M. J. M., Bovenhuis, H., Hettinga, K. A., van Valenberg, H. J. F., & van Arendonk, J. A. M. (2009) · Journal of Dairy Science · doi:10.3168/jds.2009-2456 · Cited by 133
Benn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 133
Lintner, N. G., McClure, K. F., Petersen, D. N., Londregan, A. T., Piotrowski, D. W., Wei, L., Xiao, J., Bolt, M. W., Loria, P. M., Maguire, B. A., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001882 · Cited by 132
Balder, J. W., de Vries, J. K., Nolte, I. M., Lansberg, P. J., Kuivenhoven, J. A., & Kamphuisen, P. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.007 · Cited by 132
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 131
Peterson, A. S., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.e800008-jlr200 · Cited by 131
Fasano, T., Cefalu, A. B., Leo, E. D., Noto, D., Pollaccia, D., Bocchi, L., Valenti, V., Bonardi, R., Guardamagna, O., Averna, M. R., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255311.26383.2f · Cited by 129
Prins, B. P., Kuchenbaecker, K. B., Bao, Y., Smart, M., Zabaneh, D., Fatemifar, G., Luan, J., Wareham, N. J., Scott, R. A., Perry, J. R. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10812-1 · Cited by 128
Reilly, J. P., Wang, F., Jones, T. K., Palakshappa, J. A., Anderson, B. J., Shashaty, M. G. S., Dunn, T. G., Johansson, E. D., Riley, T. R., Lim, B., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5328-0 · Cited by 128
Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 128
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. X., Ye, B., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N., et al. (2019) · doi:10.1101/572347 · Cited by 110
Tarugi, P., & Averna, M. R. (2011) · Advances in clinical chemistry · doi:10.1016/b978-0-12-387025-4.00004-2 · Cited by 127
The evolution of domain arrangements in proteins and interaction networks
Bornberg‐Bauer, E., Beaussart, F., Kummerfeld, S., Teichmann, S. A., & Weiner, J. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4416-1 · Cited by 127
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Langhi, C., May, C. L., Kourimate, S., Caron, S., Staels, B., Krempf, M., Costet, P., & Cariou, B. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.038 · Cited by 127
Tai, M., Chen, P., Chen, P., Wu, M., Ho, C., & Yen, J. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400366 · Cited by 126
Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study
DeBoever, C., Tanigawa, Y., Lindholm, M. E., McInnes, G., Lavertu, A., Ingelsson, E., Chang, C. C., Ashley, E. A., Bustamante, C. D., Daly, M. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03910-9 · Cited by 125
The effect of LRRK2 loss-of-function variants in humans
Whiffin, N., Armean, I. M., Kleinman, A., Marshall, J. L., Minikel, E. V., Goodrich, J. K., Quaife, N. M., Cole, J. B., Wang, Q. S., Karczewski, K. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0893-5 · Cited by 126
An oral antisense oligonucleotide for PCSK9 inhibition
Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L. C., Rosengren, B. E., Kakol‐Palm, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9117 · Cited by 125
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Metadata
- Authors
- Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- Howard Hughes Medical Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1264-1272
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2067539811
- Semantic Scholar
- 5cb1ad66116f87a0743739413b3b5f7f633657f8
- Cited by
- 3,181
- References
- 27
- Citations by year
- 2026: 130 · 2025: 121 · 2024: 150 · 2023: 182 · 2022: 169 · 2021: 175 · 2020: 193 · 2019: 180 · 2018: 210 · 2017: 229 · 2016: 235 · 2015: 244 · 2014: 171 · 2013: 145 · 2012: 126
- FWCI
- 104.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- W. M. Keck Foundation
- Donald W. Reynolds Foundation
- National Institutes of Health (n01hc55021-47-0-1, n01hc55020-39-0-0, n01hc55016-37-0-0, n01hc055022-024, n01hc55019-35-0-1, n01hc55018-38-0-1, N01-HC55020, N01-HC-55021, HL20948, N01-HC-55019, N01-HC-55022, N01-HC55016, N01-HC55018, N01-HC-55015, n01hc55015-48-0-1)
- National Heart, Lung, and Blood Institute (N01-HC55022, N01-HC-55018, HL-20948, N01 HC 55020, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022, N01 HC 55019, N01-HC55016, P01HL020948, N01‐HC‐55015, N01-HC55021)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, LDL cholesterol, coronary artery disease, myocardial infarction, coronary revascularization, nonsense mutation, genetic variants, LDL cholesterol lowering, cardiovascular risk, Atherosclerosis Risk in Communities Study, black and white populations
- MeSH terms
- Proprotein Convertase 9, Black or African American, Carotid Arteries, Coronary Disease, Female, Gene Frequency, Genotype, Humans, Hypolipoproteinemias, Cholesterol, LDL, Male, Middle Aged, Risk, Serine Endopeptidases, United States, Genetic Variation, Cohort Studies, Incidence, Proportional Hazards Models, Codon, Nonsense, Proprotein Convertases, Black People, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
